Welcome to our dedicated page for Aurinia Pharmace SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aurinia Pharmaceuticals Inc.'s SEC filings document the formal reporting record for a Canada-incorporated biopharmaceutical company commercializing LUPKYNIS and developing autoimmune-disease therapies. 8-K filings furnish operating and financial results, product revenue, license, collaboration and royalty revenue, research and development spending, guidance-related exhibits and other material-event disclosures.
The filings also cover proxy governance, executive appointments and compensatory arrangements, shareholder voting matters, capital-structure disclosures, share repurchase activity and material agreements. Recent transaction records include completed acquisition activity, tender-offer and merger mechanics, and contingent value right terms.
Aurinia Pharmaceuticals Inc. reported insider equity activity by Chief Financial Officer Joseph M. Miller. On February 27, 2026, he received a grant of 95,700 employee stock options with an exercise price of $0.0000 per share and an award of 57,229 shares of common stock at no cost. The options vest one-third after twelve months from the grant date, with the remaining two-thirds vesting in twenty-four equal monthly installments.
Each performance right associated with these awards represents a contingent right to receive one common share, vesting in four tranches as the share price reaches progressively higher targets, each with a one-year retention period. On March 2, 2026, 37,511 common shares at $14.21 per share were withheld as a tax-withholding disposition to satisfy tax obligations upon vesting of restricted stock units, leaving Miller with 576,421 directly held common shares.
Aurinia Pharmaceuticals Inc. Chief Operating Officer Matthew Maxwell Donley reported equity compensation and related tax withholding transactions. On February 27, 2026, he received a grant of 97,256 employee stock options at an exercise price of $0.00 per share and a grant of 58,160 shares of common stock at no cost, both held directly.
Following the stock award, his directly held common stock position increased to 721,060 shares. On March 2, 2026, 40,761 common shares valued at $14.21 per share were disposed of through a tax-withholding disposition to satisfy tax obligations upon vesting of restricted stock units, leaving 680,299 common shares held directly.
Aurinia Pharmaceuticals Inc. reported insider equity activity by Chief Executive Officer Peter Greenleaf. He received a grant of 328,424 employee stock options at an exercise price of $0.0000 per share, with one-third vesting twelve months from the grant date and the remainder vesting in twenty-four equal monthly installments thereafter.
On the same grant date, he also acquired 196,403 shares of common stock through an award. Separately, 100,890 common shares were disposed of to cover tax withholding obligations upon the vesting of restricted stock units. Following these transactions, he directly owned 1,840,379 common shares.
Aurinia Pharmaceuticals Inc. reported that SVP and Chief Medical Officer Greg Keenan received new equity awards on February 27, 2026. He was granted stock options for 67,870 shares at an exercise price of $0, increasing his option holdings to 67,870 shares.
He also acquired 40,586 shares of common stock as a grant or award at a stated price of $0, bringing his directly held common shares to 162,518. Footnotes explain that related performance rights vest in tranches based on share price targets and time-based vesting schedules.
Aurinia Pharmaceuticals Inc. executive vice president and general counsel Stephen P. Robertson reported multiple equity transactions. On February 27, 2026, he received a grant of 98,813 employee stock options with a $0 exercise price and a separate award of 59,090 common shares, both held directly.
On March 2, 2026, 36,525 common shares were disposed of to satisfy tax withholding obligations upon vesting of restricted stock units, at a price of $14.21 per share. After these transactions, he directly owned 505,861 common shares.
Aurinia Pharmaceuticals reports strong 2025 growth built around its lupus nephritis drug LUPKYNIS and a solid cash position. Net product sales reached $271.3 million, up 25% from 2024, driven by U.S. specialty pharmacy distribution and supply to its partner Otsuka for Europe and Japan.
Cash flows from operating activities rose to $135.7 million, a 206% increase, supporting a year-end cash, cash equivalents, restricted cash and investment balance of $398.0 million. Aurinia repurchased 12.2 million common shares for $98.2 million, reflecting active capital return alongside continued investment in its pipeline.
The company highlights LUPKYNIS’ clinical profile, updated treatment guidelines that favor early aggressive therapy, extensive patent and exclusivity protections, and an expanding autoimmune pipeline led by aritinercept, while acknowledging competitive, patent-challenge and reimbursement risks.
Aurinia Pharmaceuticals reported strong growth for 2025, driven by its lupus nephritis drug LUPKYNIS. Total revenue reached $283.1 million for the year, up 20% from 2024, with LUPKYNIS net product sales rising 25% to $271.3 million.
The company moved to solid profitability, with 2025 net income of $287.2 million versus $5.8 million a year earlier, helped by a large income tax benefit from releasing a valuation allowance on deferred tax assets. Cash, cash equivalents, restricted cash and investments were $398.0 million as of December 31, 2025, after repurchasing 12.2 million common shares for $98.2 million. For 2026, Aurinia guides to total revenue of $315–$325 million and LUPKYNIS net product sales of $305–$315 million, implying low- to mid-teens percentage growth.
Aurinia Pharmaceuticals Inc. insider activity: Chief Operating Officer Matthew Maxwell Donley reported a tax-related share disposition tied to equity compensation. On this Form 4, 32,901 shares of common stock were withheld at $14.4000 per share to satisfy tax obligations upon the vesting of restricted stock units. This was an automatic tax-withholding disposition, not an open-market trade, and Donley continued to hold 662,900 common shares directly after the transaction.
Aurinia Pharmaceuticals Inc. Chief Executive Officer Peter Greenleaf reported a Form 4 transaction involving company common stock. On February 20, 2026, 100,171 shares were disposed of at $14.40 per share in a tax-withholding disposition, meaning shares were withheld to cover tax obligations upon vesting of restricted stock units rather than sold in an open-market trade. After this transaction, Greenleaf directly owned 1,744,866 common shares.
Aurinia Pharmaceuticals Inc. Chief Financial Officer Joseph M. Miller reported a tax-related share disposition. On the vesting of restricted stock units, 32,424 shares of common stock were withheld at $14.40 per share to cover tax obligations, according to the footnote. After this withholding transaction, Miller directly owned 556,703 common shares.